<p><strong><em>公司推进其使命，提供下一代糖尿病管理解决方案并扩大全球市场渗透</em></strong></p>
<p><strong><em>下一代柱技术提高了效率，扩大了经常性收入潜力，并增强了 Trinity Biotech 在超过 20 亿美元的 HbA1c 市场中的竞争地位</em></strong></p>
<p>都柏林，2025 年 12 月 15 日（全球新闻稿）——Trinity Biotech plc（纳斯达克：TRIB）是一家专注于人类诊断和糖尿病管理解决方案的商业阶段生物技术公司，包括可穿戴生物传感器。今天宣布已在多个国家获得监管许可，能够扩大其下一代高容量 HbA1c 柱系统的推广，该系统现已在包括美国在内的 10 多个国家上市。升级后的系统显著提高了检测通量，改善了操作效率，并支持更大的经常性收入机会和利润扩展，因为公司在不断增长的全球 HbA1c 市场中巩固了其领导地位。</p>
<p>全球实验室 HbA1c 市场目前估计年价值超过 20 亿美元，预计到 2030 年将超过 35 亿美元。这一 HbA1c 市场的预期增长主要是由于糖尿病的日益普遍。</p>
<p>为 Trinity Biotech 的 Premier Hb9210 分析仪设计的公司专用实验室 HbA1c 解决方案，升级后的柱系统提供的检测能力是现有柱系统的四倍，并通过改善稳定性和减少维护需求来最小化仪器停机时间。这些操作上的提升为临床实验室创造了更高效的工作流程，并支持该平台的更广泛采用。</p>
<p>主要亮点：</p>
<ul>
<li>减少停机时间，提高操作效率，实现更高的通量。</li>
<li>增强的柱稳定性，最小化维护中断，减轻操作人员的工作负担。</li>
<li>最新的软件更新实现了常规任务的额外自动化，提高了生产力和成本节约。</li>
</ul>
<p>Trinity Biotech 的 Premier Hb9210 解决方案继续被认可为 HbA1c 检测的黄金标准，已发表的同行评审科学比较研究持续确认该公司 HbA1c 分析仪系统的强大临床表现。此外，最近由诊断与实验室医学协会发表的一篇文章指出_“尽管如此，BAC（Trinity Biotech）仍然是目前市场上 HbA1c 特异性最高的方法。”_</p>
<p>“在包括美国在内的关键市场推出这一先进系统，使 Trinity Biotech 能够在全球糖尿病护理领域捕捉更多增长机会，” Trinity Biotech 首席执行官兼总裁 John Gillard 表示。“更高的容量、减少的停机时间和自动化的结合为实验室创造了一个引人注目的价值主张，我们预计在关键市场的强劲采用将推动长期股东价值。”</p>
<p>Trinity Biotech 继续与客户和监管机构密切合作，扩大在其他国家的可用性，强化其对全球市场渗透和糖尿病护理创新的承诺。</p>
<p><strong>前瞻性声明</strong></p>
<p>本发布包含根据 1995 年《私人证券诉讼改革法》（“改革法”）的定义构成的 “前瞻性声明”，包括但不限于与 Trinity Biotech 的现金状况、财务资源和未来增长潜力、新或计划产品的市场接受度和渗透率以及未来经常性收入和运营结果相关的声明。Trinity Biotech 主张根据改革法的前瞻性声明安全港的保护。这些前瞻性声明通常以 “可能”、“相信”、“预测”、“期望”、“预期” 或类似含义的词语为特征，并不反映历史事实。本发布中包含的具体前瞻性声明可能受到风险和不确定性的影响，包括但不限于我们利用 Waveform 交易和最近收购的能力、我们在纳斯达克证券市场的持续上市、我们在未来实现盈利运营的能力、COVID-19 及其变种的传播影响、美国政府对 Trinity Biotech 生产的 HIV 测试的资金可能暂停和/或中断、公司分销商的潜在过剩库存水平和库存失衡、与 Trinity Biotech 的设施或制造运营相关的损失或系统故障、汇率波动对国际运营的影响、季度运营结果的波动、对供应商的依赖、Trinity Biotech 产品和服务的市场接受度、产品的持续开发、所需的政府批准、与大规模无缺陷生产和分销其产品相关的风险、与第三方制造的新仪器引入相关的风险、在人体诊断市场竞争相关的风险、与保护 Trinity Biotech 知识产权或第三方提出的知识产权侵权索赔相关的风险以及与美国经济状况相关的风险，以及在 Trinity Biotech 截至 2024 年 12 月 31 日的财政年度的 20-F 表格年报和 Trinity Biotech 不时向美国证券交易委员会提交的其他定期报告中详细列出的 “风险因素”。前瞻性声明仅在声明发布之日有效。Trinity Biotech 不承担并特别声明不承担更新任何前瞻性声明的义务。</p>
<p><strong>关于 Trinity Biotech</strong></p>
<p>Trinity Biotech 是一家商业阶段的生物技术公司，专注于糖尿病管理解决方案和人类诊断，包括可穿戴生物传感器。该公司开发、收购、制造和销售诊断系统，包括用于即时护理和临床实验室领域的试剂和仪器，并最近通过收购 Waveform Technologies Inc.的生物传感器资产进入可穿戴生物传感器行业，计划开发一系列生物传感器设备及相关服务，首个产品为连续血糖监测设备。我们的产品用于检测传染病，并量化血清、血浆和全血中的糖化血红蛋白 A1c 及其他化学参数的水平。Trinity Biotech 在美国直接销售，并通过全球 75 个国家的国际分销商和战略合作伙伴网络进行销售。有关更多信息，请访问公司网站：www.trinitybiotech.com。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>联系方式：</strong></td>
<td><strong>Trinity Biotech plc</strong></td>
<td><strong>RedChip Companies Inc.</strong></td>
</tr>
<tr>
<td></td>
<td>Gary Keating, Ph.D.<br/> (353)-1-2769800</td>
<td>Dave Gentry, CEO <br/> (1)-407-644-4256<br/> (1)-800-RED-CHIP (733-2447)<br/>TRIB@redchip.com</td>
</tr>
</tbody>
</table>
<p>\<em>\</em>\______________________</p>
<p>1 <em>https://www.maximizemarketresearch.com/market-report/global-hba1c-laboratory-tests-market/81466/</em> 2 <em>https://doi.org/10.1080/00365513.2023.2281400</em> <em>和</em> <em>https://doi.org/10.1080/03630269.2025.2524437</em></p>
<p>3 <em>https://myadlm.org/cln/articles/2025/septemberoctober/navigating-hemoglobin-a1c-measurements-for-diabetes-care?utm_campaign=september-cln-monthly-email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--H-b8nqWXfE5QzwxN7g7ng4LhJzv0dDYVj2Cvg-NZlV7uT8_-w9cxM7lAzfzVYdEg1c2QDGQmD_hAXRIAHVcYtRVxNxLe4bPax9TWmCPC1IGjFkjQ&amp;_hsmi=382763562&amp;utm_content=382763562&amp;utm_source=hs_email</em></p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qSXpOaU0zTXpJeE9EVTJJekl3TVRnNU1UVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qSXpOaU0zTXpJeE9EVTJJekl3TVRnNU1UVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODJkMjAyYTktM2M0Ny00MDM0LWJmNzgtODUyOWQ2NmU0ODA3LTEwMzA0ODgtMjAyNS0xMi0xNS1lbg==/tiny/Trinity-Biotech-plc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODJkMjAyYTktM2M0Ny00MDM0LWJmNzgtODUyOWQ2NmU0ODA3LTEwMzA0ODgtMjAyNS0xMi0xNS1lbg==/tiny/Trinity-Biotech-plc.png"/></p>

Trinity生物科技-A

<p>Trinity 生物科技-A 已获得其高容量 HbA1c 柱系统的监管批准，扩大在包括美国在内的 10 多个国家的推广。该系统提高了检测效率和收入潜力，巩固了其在超过 20 亿美元的 HbA1c 市场中的地位。升级后的系统提供四倍的检测能力，减少了停机时间，并改善了稳定性，支持更广泛的采用和长期股东价值</p>

<p><strong><em>Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration</em></strong></p>
<div class="lb-trans"><p><strong><em>公司推进其使命，提供下一代糖尿病管理解决方案并扩大全球市场渗透</em></strong></p>
</div><p><strong><em>Next-generation column technology enhances efficiency, expands recurring revenue potential, and strengthens Trinity Biotech’s competitive position in the $2B+ HbA1c market</em></strong></p>
<div class="lb-trans"><p><strong><em>下一代柱技术提高了效率，扩大了经常性收入潜力，并增强了 Trinity Biotech 在超过 20 亿美元的 HbA1c 市场中的竞争地位</em></strong></p>
</div><p>DUBLIN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has secured regulatory clearances in multiple countries, enabling the expanded rollout of its next-generation high-capacity HbA1c column system for the Premier Hb9210 analyzer which is now available in more than 10 countries, including the United States. The upgraded system significantly increases testing throughput, improves operational efficiency, and supports greater recurring revenue opportunities and margin expansion as the company strengthens its leadership position in the growing global HbA1c market.</p>
<div class="lb-trans"><p>都柏林，2025 年 12 月 15 日（全球新闻稿）——Trinity Biotech plc（纳斯达克：TRIB）是一家专注于人类诊断和糖尿病管理解决方案的商业阶段生物技术公司，包括可穿戴生物传感器。今天宣布已在多个国家获得监管许可，能够扩大其下一代高容量 HbA1c 柱系统的推广，该系统现已在包括美国在内的 10 多个国家上市。升级后的系统显著提高了检测通量，改善了操作效率，并支持更大的经常性收入机会和利润扩展，因为公司在不断增长的全球 HbA1c 市场中巩固了其领导地位。</p>
</div><p>The global laboratory HbA1c market is estimated to be currently worth over $2 billion annually and is expected to grow to exceed $3.5 billion by 2030. This expected rise in the HbA1c market is primarily driven by the increasing prevalence of diabetes1.</p>
<div class="lb-trans"><p>全球实验室 HbA1c 市场目前估计年价值超过 20 亿美元，预计到 2030 年将超过 35 亿美元。这一 HbA1c 市场的预期增长主要是由于糖尿病的日益普遍。</p>
</div><p>Designed for Trinity Biotech’s Premier Hb9210 analyzer, the company’s dedicated laboratory HbA1c solution, the upgraded column system delivers up to four times the testing capacity compared to the existing column system and minimizes instrument downtime through improved stability and reduced maintenance requirements. These operational gains create a more efficient workflow for clinical laboratories and support broader adoption of the platform.</p>
<div class="lb-trans"><p>为 Trinity Biotech 的 Premier Hb9210 分析仪设计的公司专用实验室 HbA1c 解决方案，升级后的柱系统提供的检测能力是现有柱系统的四倍，并通过改善稳定性和减少维护需求来最小化仪器停机时间。这些操作上的提升为临床实验室创造了更高效的工作流程，并支持该平台的更广泛采用。</p>
</div><p>Key Highlights:</p>
<div class="lb-trans"><p>主要亮点：</p>
</div><ul>
<li>Reduced downtime and improved operational efficiency, enabling higher throughput.</li>
<li>Increased column stability, minimizing maintenance interruptions and reducing operator workload.</li>
<li>The latest software update delivers additional automation of routine tasks enabling greater productivity and cost savings.</li>
</ul>
<div class="lb-trans"><ul>
<li>减少停机时间，提高操作效率，实现更高的通量。</li>
<li>增强的柱稳定性，最小化维护中断，减轻操作人员的工作负担。</li>
<li>最新的软件更新实现了常规任务的额外自动化，提高了生产力和成本节约。</li>
</ul>
</div><p>Trinity Biotech’s Premier Hb9210 solution continues to be recognized as a gold standard in HbA1c testing, with published peer-reviewed scientific comparative studies continuing to confirm the strong clinical performance of the company’s HbA1c analyzer system2. In addition, a recent article published by the Association for Diagnostics and Laboratory Medicine states <em>“Still, BAC (Trinity Biotech) remains the method with the highest specificity for HbA1c currently on the market.” 3</em></p>
<div class="lb-trans"><p>Trinity Biotech 的 Premier Hb9210 解决方案继续被认可为 HbA1c 检测的黄金标准，已发表的同行评审科学比较研究持续确认该公司 HbA1c 分析仪系统的强大临床表现。此外，最近由诊断与实验室医学协会发表的一篇文章指出_“尽管如此，BAC（Trinity Biotech）仍然是目前市场上 HbA1c 特异性最高的方法。”_</p>
</div><p>“Launching this advanced system in key markets, including the U.S., positions Trinity Biotech to capture further growth opportunities in the global diabetes care segment,” said John Gillard, CEO and President of Trinity Biotech. “The combination of higher capacity, reduced downtime, and automation creates a compelling value proposition for laboratories, and we expect strong adoption in key markets to drive long-term shareholder value.”</p>
<div class="lb-trans"><p>“在包括美国在内的关键市场推出这一先进系统，使 Trinity Biotech 能够在全球糖尿病护理领域捕捉更多增长机会，” Trinity Biotech 首席执行官兼总裁 John Gillard 表示。“更高的容量、减少的停机时间和自动化的结合为实验室创造了一个引人注目的价值主张，我们预计在关键市场的强劲采用将推动长期股东价值。”</p>
</div><p>Trinity Biotech continues to work closely with customers and regulatory authorities to expand availability into additional countries, reinforcing its commitment to global market penetration and innovation in diabetes care.</p>
<div class="lb-trans"><p>Trinity Biotech 继续与客户和监管机构密切合作，扩大在其他国家的可用性，强化其对全球市场渗透和糖尿病护理创新的承诺。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.</p>
<div class="lb-trans"><p>本发布包含根据 1995 年《私人证券诉讼改革法》（“改革法”）的定义构成的 “前瞻性声明”，包括但不限于与 Trinity Biotech 的现金状况、财务资源和未来增长潜力、新或计划产品的市场接受度和渗透率以及未来经常性收入和运营结果相关的声明。Trinity Biotech 主张根据改革法的前瞻性声明安全港的保护。这些前瞻性声明通常以 “可能”、“相信”、“预测”、“期望”、“预期” 或类似含义的词语为特征，并不反映历史事实。本发布中包含的具体前瞻性声明可能受到风险和不确定性的影响，包括但不限于我们利用 Waveform 交易和最近收购的能力、我们在纳斯达克证券市场的持续上市、我们在未来实现盈利运营的能力、COVID-19 及其变种的传播影响、美国政府对 Trinity Biotech 生产的 HIV 测试的资金可能暂停和/或中断、公司分销商的潜在过剩库存水平和库存失衡、与 Trinity Biotech 的设施或制造运营相关的损失或系统故障、汇率波动对国际运营的影响、季度运营结果的波动、对供应商的依赖、Trinity Biotech 产品和服务的市场接受度、产品的持续开发、所需的政府批准、与大规模无缺陷生产和分销其产品相关的风险、与第三方制造的新仪器引入相关的风险、在人体诊断市场竞争相关的风险、与保护 Trinity Biotech 知识产权或第三方提出的知识产权侵权索赔相关的风险以及与美国经济状况相关的风险，以及在 Trinity Biotech 截至 2024 年 12 月 31 日的财政年度的 20-F 表格年报和 Trinity Biotech 不时向美国证券交易委员会提交的其他定期报告中详细列出的 “风险因素”。前瞻性声明仅在声明发布之日有效。Trinity Biotech 不承担并特别声明不承担更新任何前瞻性声明的义务。</p>
</div><p><strong>About Trinity Biotech</strong></p>
<div class="lb-trans"><p><strong>关于 Trinity Biotech</strong></p>
</div><p>Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.</p>
<div class="lb-trans"><p>Trinity Biotech 是一家商业阶段的生物技术公司，专注于糖尿病管理解决方案和人类诊断，包括可穿戴生物传感器。该公司开发、收购、制造和销售诊断系统，包括用于即时护理和临床实验室领域的试剂和仪器，并最近通过收购 Waveform Technologies Inc.的生物传感器资产进入可穿戴生物传感器行业，计划开发一系列生物传感器设备及相关服务，首个产品为连续血糖监测设备。我们的产品用于检测传染病，并量化血清、血浆和全血中的糖化血红蛋白 A1c 及其他化学参数的水平。Trinity Biotech 在美国直接销售，并通过全球 75 个国家的国际分销商和战略合作伙伴网络进行销售。有关更多信息，请访问公司网站：www.trinitybiotech.com。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact:</strong></td>
<td><strong>Trinity Biotech plc</strong></td>
<td><strong>RedChip Companies Inc.</strong></td>
</tr>
<tr>
<td></td>
<td>Gary Keating, Ph.D.<br/> (353)-1-2769800</td>
<td>Dave Gentry, CEO <br/> (1)-407-644-4256<br/> (1)-800-RED-CHIP (733-2447)<br/>TRIB@redchip.com</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>联系方式：</strong></td>
<td><strong>Trinity Biotech plc</strong></td>
<td><strong>RedChip Companies Inc.</strong></td>
</tr>
<tr>
<td></td>
<td>Gary Keating, Ph.D.<br/> (353)-1-2769800</td>
<td>Dave Gentry, CEO <br/> (1)-407-644-4256<br/> (1)-800-RED-CHIP (733-2447)<br/>TRIB@redchip.com</td>
</tr>
</tbody>
</table>
</div><p>\<em>\</em>\______________________</p>
<div class="lb-trans"><p>\<em>\</em>\______________________</p>
</div><p>1 <em>https://www.maximizemarketresearch.com/market-report/global-hba1c-laboratory-tests-market/81466/</em> 2 <em>https://doi.org/10.1080/00365513.2023.2281400</em> <em>and</em> <em>https://doi.org/10.1080/03630269.2025.2524437</em></p>
<div class="lb-trans"><p>1 <em>https://www.maximizemarketresearch.com/market-report/global-hba1c-laboratory-tests-market/81466/</em> 2 <em>https://doi.org/10.1080/00365513.2023.2281400</em> <em>和</em> <em>https://doi.org/10.1080/03630269.2025.2524437</em></p>
</div><p>3 <em>https://myadlm.org/cln/articles/2025/septemberoctober/navigating-hemoglobin-a1c-measurements-for-diabetes-care?utm_campaign=september-cln-monthly-email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--H-b8nqWXfE5QzwxN7g7ng4LhJzv0dDYVj2Cvg-NZlV7uT8_-w9cxM7lAzfzVYdEg1c2QDGQmD_hAXRIAHVcYtRVxNxLe4bPax9TWmCPC1IGjFkjQ&amp;_hsmi=382763562&amp;utm_content=382763562&amp;utm_source=hs_email</em></p>
<div class="lb-trans"><p>3 <em>https://myadlm.org/cln/articles/2025/septemberoctober/navigating-hemoglobin-a1c-measurements-for-diabetes-care?utm_campaign=september-cln-monthly-email&amp;utm_medium=email&amp;_hsenc=p2ANqtz--H-b8nqWXfE5QzwxN7g7ng4LhJzv0dDYVj2Cvg-NZlV7uT8_-w9cxM7lAzfzVYdEg1c2QDGQmD_hAXRIAHVcYtRVxNxLe4bPax9TWmCPC1IGjFkjQ&amp;_hsmi=382763562&amp;utm_content=382763562&amp;utm_source=hs_email</em></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qSXpOaU0zTXpJeE9EVTJJekl3TVRnNU1UVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMjIzNiM3MzIxODU2IzIwMTg5MTU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODJkMjAyYTktM2M0Ny00MDM0LWJmNzgtODUyOWQ2NmU0ODA3LTEwMzA0ODgtMjAyNS0xMi0xNS1lbg==/tiny/Trinity-Biotech-plc.png" alt="" original-src="https://ml.globenewswire.com/media/ODJkMjAyYTktM2M0Ny00MDM0LWJmNzgtODUyOWQ2NmU0ODA3LTEwMzA0ODgtMjAyNS0xMi0xNS1lbg==/tiny/Trinity-Biotech-plc.png"/></p>

Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances | TRIB Stock News

Trinity 生物科技-A 在获得监管批准后，扩大了其 FDA 批准的 HbA1c 检测解决方案的高容量柱系统的全球推广 | TRIB 股票新闻